Cerdulatinib

Protocol Number: Portola — NCT01994382 (www.clinicaltrials.gov)
A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib in Patients with Relapsed/Refractor Chronc Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma. – OPEN TO ENROLLMENT

Rituximab +/- Ibruitinib

Protocol Number: The USOncologyNetwork – 16176 (www.clinicaltrials.gov)
A Multicenter, Randomized, Double-blind Placebo-controlled Phase 3 Study of Bruton’s Tyrosine Kinas (BTK) Inhibitor, Ibrutinib, in Combination with Rituximb versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma – OPEN TO ENROLLMENT

Polatuzumab Vedotin, Rituximab, CHP, R-CHOP

Protocol Number: USOncology 17-050 (www.clinicaltrials.gov)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma – OPEN TO ENROLLMENT